Covid-19 mutation discovered
Scientists have identified a SARS-CoV-2 mutation that allows the virus to escape recognition by several antibodies manufactured as COVID-19 treatments, Nature informs.
The designer therapies called monoclonal antibodies are modeled on naturally occurring immune molecules. Jesse Bloom at the Fred Hutchinson Cancer Research Center in Seattle, Washington, and his colleagues mapped every possible SARS-CoV-2 mutation that could prevent binding by three monoclonal antibodies: one manufactured by Eli Lilly in Indianapolis, Indiana, and the two in a ‘cocktail’ made by Regeneron in Tarrytown, New York.
According to Nature, mutations affect a protein segment called the receptor-binding domain, which the virus uses to bind to and enter cells. The researchers found one mutation that caused the virus to escape recognition by Regeneron’s antibody cocktail and a few others that helped it to escape one of the three antibodies.